查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404639

基因治療市場規模、佔有率、趨勢分析報告：按適應症、載體類型、地區、細分市場預測，2024-2030

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type (Lentivirus, Adenovirus), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 162 Pages | 商品交期: 2-10個工作天內

價格

基因治療市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球基因治療市場規模將達到295.1億美元，2023年至2030年複合年成長率為19.5%。

基於基因治療的發現數量的增加、該領域投資的增加以及基因治療產品核准率的提高推動了市場的開拓。據世界衛生組織稱，到 2025 年，每年將核准10 至 20 種新的細胞和基因療法。

重組DNA技術的持續發展預計將在未來幾年提高基因治療的效率。因此，重組DNA技術的不斷進步有望擴大基因治療臨床試驗的數量。這些進步主要發生在各種基因編輯工具和表達系統的背景下，以加強產品的研究和開發。 CRISPR/Cas9 核酸酶、ZFN 和 TALEN 的出現使得簡單而精確的基因組編輯成為可能。因此，近年來基因編輯領域出現了大量的研究活動，預計這也將對基因治療市場的成長產生影響。

基因治療市場的成長預計將大大受益於癌症盛行率的增加。每年癌症患者和相關死亡人數的持續增加強調了開發強力的治療解決方案的必要性。 2020年，全球約有1,810萬新癌症患者。其中，男性 930 萬，女性 880 萬。腫瘤遺傳學研究的持續進展預計將提供與癌症相關的分子特徵的大量資訊，這反過來又將支持正在進行的癌症治療臨床試驗。

隨著對強力的疾病治療療法的需求增加，公司專注於加速研究和開發在基因組層級上針對疾病原因的有效基因療法。此外，美國FDA 持續透過一系列與產品製造相關的政策支持該領域的創新。 2020 年 1 月，FDA 發布了安全高效的產品製造和臨床開發的六項最終指南。

此外，細胞和基因治療的設施擴建是推動基因治療市場成長的關鍵因素之一。一些用於基因治療製造的自有設施和 CDMO 已開始投資以提高其生產能力，預計這將為市場參與者創造利潤豐厚的機會。例如，2022 年 4 月，FDA核准了諾華北卡羅來納州達勒姆工廠的商業許可。該批准授權這家佔地 170,000 平方英尺的工廠生產、測試和銷售 Zolgenma，並生產用於當前和未來臨床試驗的治療產品。

基因治療市場報告亮點

  • 到 2023 年，AAV 細分市場的銷售貢獻將達到 22%。多家生物製藥公司為基於 AAV 的基因治療產品開發提供病毒載體平台。
  • 有跡象表明，脊髓性肌肉萎縮症（SMA）領域在 2023 年以 46.8% 的佔有率佔據市場主導地位。脊髓性肌肉萎縮症是一種罕見但最常見的嬰幼兒致命遺傳性疾病之一。
  • 地中海型貧血 B/SCD 預計在預測期內複合年成長率最快，達到 38.3%。 SCD 和 B 地中海貧血的基因治療是基於基因改造造血幹細胞移植。
  • 2023年，北美以65.2%的最大銷售佔有率主導市場。在預測期內，就核准數量和收益而言，該地區預計將成為最大的基因療法常規製造商。
  • 據估計，從 2024 年到 2030 年，歐洲將成為成長最快的地區。這是由於大量人口的醫療需求未被滿足，以及對治療罕見但日益流行的疾病的新技術的需求不斷成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 產業分析工具

第4章 指標業務分析

  • 基因治療市場：適應性變異分析
  • 急性淋巴性白血病
  • 遺傳性視網膜疾病
  • 大B細胞淋巴瘤
  • Adenosine deaminase(Ada) 缺乏的嚴重複合型免疫力缺乏(Scid)
  • 黑色素瘤（病變）
  • 嚴重BETA地中海貧血/鐮狀細胞疾病 (Scd)
  • 頭頸鱗狀細胞癌
  • 周邊動脈疾病
  • 脊髓性肌肉萎縮症（SMA）
  • 其他

第5章向量型業務分析

  • 基因治療市場：載體類型變異分析
  • 慢病毒載體
  • 腺結合病毒(Aav) 載體
  • 逆轉錄病毒載體
  • 改良單純皰疹病毒
  • 腺病毒載體
  • 非病毒質粒載體
  • 其他

第6章 區域業務分析

  • 2023年及2030年按地區分類的基因治療市場佔有率
  • 北美洲
    • 北美基因治療市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲基因治療市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 亞太基因治療市場，2018-2030
    • 日本
    • 中國
    • 澳洲
  • 世界其他地區
    • 世界其他地區基因治療市場，2018-2030

第7章競爭形勢

  • 公司分類
  • 策略規劃
  • 2023 年公司市場佔有率分析
  • 公司簡介
    • REGENXBIO, INC
    • OXFORD BIOMEDICA PLC
    • VOYAGER THERAPEUTICS
    • HUMAN STEM CELLS INSTITUTE
    • DIMENSION THERAPEUTICS, INC
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • APPLIED GENETIC TECHNOLOGIES CORPORATION
    • F. HOFFMANN-LA ROCHE LTD
    • BLUEBIRD BIO, INC
    • NOVARTIS AG
    • TAXUS CARDIUM PHARMACEUTICALS GROUP, INC.（GENE BIOTHERAPEUTICS）
    • UNIQURE NV
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • CELLECTIS SA
    • SANGAMO THERAPEUTICS, INC.
    • ORCHARD THERAPEUTICS
    • GILEAD LIFESCIENCES, INC.
    • BENITEC BIOPHARMA
    • SIBIONO GENETECH CO., LTD
    • SHANGHAI SUNWAY BIOTECH CO., LTD.
    • GENSIGHT BIOLOGICS SA
    • TRANSGENE
    • CALIMMUNE, INC
    • EPEIUS BIOTECHNOLOGIES CORP.
    • ASTELLAS PHARMA INC
    • AMERICAN GENE TECHNOLOGIES
    • BIOMARIN PHARMACEUTICALS, INC
Product Code: GVR-2-68038-179-5

Gene Therapy Market Growth & Trends:

The global gene therapy market is expected to reach USD 29.51 billion by 2030, registering a CAGR of 19.5% from 2023 to 2030, according to a new report by Grand View Research, Inc. The development of the market is owing to an increase in the number of gene therapy-based discoveries, increasing investment in this sector, and rising approval of gene therapy products. According to the WHO, 10 to 20 new cell and gene therapies are expected to be approved each year by 2025.

Continuous developments in recombinant DNA technology are anticipated to enhance the efficiency of gene therapy in the coming years. Hence, ongoing progresses in recombinant DNA technology are anticipated to expand the number of ongoing clinical trials for gene therapy. Primarily, these advancements are taking place in the context of various gene-editing tools and expression systems to augment the R&D for products. The advent of CRISPR/Cas9 nuclease, ZFN, and TALEN allows easy & precise genome editing. As a result, in recent times, the gene-editing space has witnessed a substantial number of research activities, which, in turn, is expected to influence the growth of the gene therapy market.

The growth of the gene therapy market is expected to be majorly benefitted from the increasing prevalence of cancer. The ongoing increase in cancer patients and related death per year emphasizes the essential for the development of robust treatment solutions. In 2020, there were around 18.1 million new cases of cancer worldwide. 9.3 million of these cases involved men, while 8.8 million involved women. Continuing developments in tumor genetic studies have delivered substantial information about cancer-related molecular signatures, which in turn, is expected to support ongoing clinical trials for cancer therapeutics.

With rising demand for robust disease treatment therapies, companies have focused their efforts to accelerate R&D for effective genetic therapies that target the cause of disease at a genomic level. . Furthermore, the U.S. FDA provides constant support for innovations in this sector via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe and efficient products.

Furthermore, facility expansion for cell and gene therapies is one of the major factors driving the gene therapy market growth. Several in-house facilities and CDMOs for gene therapy manufacturing have begun investing to enhance their production capacity, which, in turn, is anticipated to create lucrative opportunities for market players. For instance, in April 2022, the FDA approved commercial licensure approval to Novartis for its Durham, N.C. site. This approval permits the 170,000 square-foot facility to make, test, and issue commercial Zolgensma, as well as manufacture therapy products for current & upcoming clinical trials.

Gene Therapy Market Report Highlights:

  • The AAV segment shows a significant revenue contribution of 22% in 2023. Several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy product.
  • By indication, the spinal muscular atrophy (SMA) segment dominated the market in 2023 with a share of 46.8%. Although SMA is a rare disorder, it is one of the most common fatal inherited diseases of infancy.
  • The Beta-Thalassemia Major/SCD segment is anticipated to register the fastest CAGR of 38.3% over the forecast period. Gene therapy for SCD and B-thalassemia is based on transplantation of gene-modified hematopoietic stem cells.
  • North America dominated the market in 2023 with the largest revenue share of 65.2% in 2023. This region is expected to become the largest routine manufacturer of gene therapy in terms of the number of approvals and revenue generated during the forecast period.
  • Europe is estimated to be the fastest-growing regional segment from 2024 to 2030. This is attributed to its large population with unmet medical needs and increasing demand for novel technologies in the treatment of rare but increasingly prevalent diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Application & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Application & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Robust Gene Therapy Pipeline
      • 3.2.1.2. Introduction Of Technological Advancements
      • 3.2.1.3. Increasing Investment From Companies And Partnerships
      • 3.2.1.4. Growing Prevalence Of Target Diseases And Increased Demand For Innovative Medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Absence Of Effective Diagnosis Framework
      • 3.2.2.2. High Prices Of Gene Therapy
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Rising Investment For Adoptive T-Cell Transfer Approaches Of Disease Treatment
      • 3.2.3.2. Facility Expansion For Cell And Gene Therapies
      • 3.2.3.3. Technological Advancements In Manufacturing Vectors
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Indication Business Analysis

  • 4.1. Gene Therapy Market: Indication Movement Analysis
  • 4.2. Acute Lymphoblastic Leukemia
    • 4.2.1. Acute Lymphoblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.3. Inherited Retinal Disease
    • 4.3.1. Inherited Retinal Disease Market, 2018 - 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Large B-Cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.5. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid)
    • 4.5.1. Adenosine Deaminase (Ada)-Deficient Severe Combined Immunodeficiency (Scid) Market, 2018 - 2030 (USD Million)
  • 4.6. Melanoma (lesions)
    • 4.6.1. Melanoma (lesions) Market, 2018 - 2030 (USD Million)
  • 4.7. Beta-Thalassemia Major/Sickle Cell Disease (Scd)
    • 4.7.1. Beta-Thalassemia Major/Sickle Cell Disease (Scd) Market, 2018 - 2030 (USD Million)
  • 4.8. Head & Neck Squamous Cell Carcinoma
    • 4.8.1. Head & Neck Squamous Cell Carcinoma Market, 2018 - 2030 (USD Million)
  • 4.9. Peripheral arterial disease
    • 4.9.1. Peripheral arterial disease Market, 2018 - 2030 (USD Million)
  • 4.10. Spinal Muscular Atrophy (SMA)
    • 4.10.1. Spinal Muscular Atrophy (SMA) Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vector Type Business Analysis

  • 5.1. Gene Therapy Market: Vector Type Movement Analysis
  • 5.2. Lentiviral Vectors
    • 5.2.1. Lentiviral Vectors market, 2018 - 2030 (USD Million)
  • 5.3. Adeno-Associated Viral (Aav) Vectors
    • 5.3.1. Adeno-Associated Viral (Aav) Vectors market, 2018 - 2030 (USD Million)
  • 5.4. Retrovirus Vectors
    • 5.4.1. Retrovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.5. Modified Herpes Simplex Virus
    • 5.5.1. Modified Herpes Simplex Virus market, 2018 - 2030 (USD Million)
  • 5.6. Adenovirus Vectors
    • 5.6.1. Adenovirus Vectors market, 2018 - 2030 (USD Million)
  • 5.7. Non-Viral Plasmid Vector
    • 5.7.1. Non-Viral Plasmid Vector market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Gene Therapy Market Share By Region, 2023 & 2030
  • 6.2. North America
    • 6.2.1. North America Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target disease prevalence
      • 6.2.2.3. Competitive Scenario
      • 6.2.2.4. Regulatory Framework
      • 6.2.2.5. U.S. Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target disease prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Canada Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target disease prevalence
      • 6.3.2.3. Competitive Scenario
      • 6.3.2.4. Regulatory Framework
      • 6.3.2.5. UK Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target disease prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Germany Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target disease prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. France Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target disease prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Italy Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target disease prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Spain Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target disease prevalence
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Regulatory Framework
      • 6.4.2.5. Japan Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target disease prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. China Gene Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.4. Australia
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target disease prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Australia Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.5. Rest of the world
    • 6.5.1. Rest of the world Gene Therapy Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. REGENXBIO, INC
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. OXFORD BIOMEDICA PLC
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. VOYAGER THERAPEUTICS
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. HUMAN STEM CELLS INSTITUTE
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. DIMENSION THERAPEUTICS, INC
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. BRISTOL-MYERS SQUIBB COMPANY
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. SANOFI
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. APPLIED GENETIC TECHNOLOGIES CORPORATION
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. F. HOFFMANN-LA ROCHE LTD
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. BLUEBIRD BIO, INC
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. NOVARTIS AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. TAXUS CARDIUM PHARMACEUTICALS GROUP, INC. (GENE BIOTHERAPEUTICS)
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. UNIQURE N.V.
      • 7.4.13.1. Overview
      • 7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Strategic Initiatives
    • 7.4.14. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 7.4.14.1. Overview
      • 7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Strategic Initiatives
    • 7.4.15. CELLECTIS S.A.
      • 7.4.15.1. Overview
      • 7.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Strategic Initiatives
    • 7.4.16. SANGAMO THERAPEUTICS, INC.
      • 7.4.16.1. Overview
      • 7.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.16.3. Product Benchmarking
      • 7.4.16.4. Strategic Initiatives
    • 7.4.17. ORCHARD THERAPEUTICS
      • 7.4.17.1. Overview
      • 7.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.17.3. Product Benchmarking
      • 7.4.17.4. Strategic Initiatives
    • 7.4.18. GILEAD LIFESCIENCES, INC.
      • 7.4.18.1. Overview
      • 7.4.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.18.3. Product Benchmarking
      • 7.4.18.4. Strategic Initiatives
    • 7.4.19. BENITEC BIOPHARMA
      • 7.4.19.1. Overview
      • 7.4.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.19.3. Product Benchmarking
      • 7.4.19.4. Strategic Initiatives
    • 7.4.20. SIBIONO GENETECH CO., LTD
      • 7.4.20.1. Overview
      • 7.4.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.20.3. Product Benchmarking
      • 7.4.20.4. Strategic Initiatives
    • 7.4.21. SHANGHAI SUNWAY BIOTECH CO., LTD.
      • 7.4.21.1. Overview
      • 7.4.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.21.3. Product Benchmarking
      • 7.4.21.4. Strategic Initiatives
    • 7.4.22. GENSIGHT BIOLOGICS S.A.
      • 7.4.22.1. Overview
      • 7.4.22.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.22.3. Product Benchmarking
      • 7.4.22.4. Strategic Initiatives
    • 7.4.23. TRANSGENE
      • 7.4.23.1. Overview
      • 7.4.23.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.23.3. Product Benchmarking
      • 7.4.23.4. Strategic Initiatives
    • 7.4.24. CALIMMUNE, INC
      • 7.4.24.1. Overview
      • 7.4.24.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.24.3. Product Benchmarking
      • 7.4.24.4. Strategic Initiatives
    • 7.4.25. EPEIUS BIOTECHNOLOGIES CORP.
      • 7.4.25.1. Overview
      • 7.4.25.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.25.3. Product Benchmarking
      • 7.4.25.4. Strategic Initiatives
    • 7.4.26. ASTELLAS PHARMA INC
      • 7.4.26.1. Overview
      • 7.4.26.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.26.3. Product Benchmarking
      • 7.4.26.4. Strategic Initiatives
    • 7.4.27. AMERICAN GENE TECHNOLOGIES
      • 7.4.27.1. Overview
      • 7.4.27.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.27.3. Product Benchmarking
      • 7.4.27.4. Strategic Initiatives
    • 7.4.28. BIOMARIN PHARMACEUTICALS, INC
      • 7.4.28.1. Overview
      • 7.4.28.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.28.3. Product Benchmarking
      • 7.4.28.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Tables
  • Table 3 List of Secondary Sources
  • Table 4 List of Abbreviations
  • Table 5 Global Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 6 Global Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 7 Global Gene Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 10 North America Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 13 Canada Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 15 Europe Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 18 Germany Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 19 Germany Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 21 UK Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 22 France Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 23 France Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 24 Italy Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 26 Spain Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gene Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 31 China Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 32 China Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 33 Japan Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 35 South Korea Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 36 South Korea Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 37 Australia Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gene Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 RoW Gene Therapy Market by Vector Type, 2018 - 2030 (USD Million)
  • Table 40 RoW Gene Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Gene Therapy Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 Global Gene Therapy Market for Lentivirus, 2018 - 2030 (USD Million)
  • Fig. 15 Global Gene Therapy Market for AAV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Gene Therapy Market for RetroVirus & gamma RetroVirus, 2018 - 2030 (USD Million)
  • Fig. 17 Global Gene Therapy Market for Modified Herpes Simplex Virus, 2018 - 2030 (USD Million)
  • Fig. 18 Global Gene Therapy Market for Adenovirus, 2018 - 2030 (USD Million)
  • Fig. 19 Global Gene Therapy Market for Non-viral Plasmid Vector, 2018 - 2030 (USD Million)
  • Fig. 20 Global Gene Therapy Market for Other Vector Type, 2018 - 2030 (USD Million)
  • Fig. 21 Global Gene Therapy Market for Acute Lymphoblastic Leukemia (ALL), 2018 - 2030 (USD Million)
  • Fig. 22 Global Acute Lymphoblastic Leukemia (ALL) patients treated with gene therapy, 2018 - 2030
  • Fig. 23 Global Gene Therapy Market for Inherited Retinal Disease, 2018 - 2030 (USD Million)
  • Fig. 24 Global Inherited Retinal Disease patients treated with gene therapy, 2018 - 2030
  • Fig. 25 Global Gene Therapy Market for Large B-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 26 Global Large B-cell Lymphoma patients treated with gene therapy, 2018 - 2030
  • Fig. 27 Global Gene Therapy Market for ADA-SCID, 2018 - 2030 (USD Million)
  • Fig. 28 Global ADA-SCID patients treated with gene therapy, 2018 - 2030
  • Fig. 29 Global Gene Therapy Market for Melanoma (lesions), 2018 - 2030 (USD Million)
  • Fig. 30 Global Melanoma (lesions) patients treated with gene therapy, 2018 - 2030
  • Fig. 31 Global Gene Therapy Market for Beta-Thalassemia Major/SCD, 2018 - 2030 (USD Million)
  • Fig. 32 Global Beta-Thalassemia Major/SCD patients treated with gene therapy, 2018 - 2030
  • Fig. 33 Global Gene Therapy Market for Head & Neck Squamous Cell Carcinoma, 2018 - 2030 (USD Million)
  • Fig. 34 Global Head & Neck Squamous Cell Carcinoma patients treated with gene therapy, 2018 - 2030
  • Fig. 35 Global Gene Therapy Market for Peripheral arterial disease, 2018 - 2030 (USD Million)
  • Fig. 36 Global Peripheral arterial disease patients treated with gene therapy, 2018 - 2030
  • Fig. 37 Global Gene Therapy Market for Spinal Muscular Atrophy (SMA), 2018 - 2030 (USD Million)
  • Fig. 38 Global Spinal Muscular Atrophy (SMA) patients treated with gene therapy, 2018 - 2030
  • Fig. 39 Global Gene Therapy Market for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Global Other diseases patient treated with gene therapy, 2018 - 2030
  • Fig. 41 Regional Outlook, 2022 & 2030
  • Fig. 42 North America Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 44 Canada Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 45 Europe Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 46 Germany Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 47 UK Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 48 France Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 49 Italy Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 50 Spain Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 52 Japan Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 53 China Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 54 Australia Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 55 South Korea Gene Therapy Market 2018 - 2030 (USD Million)
  • Fig. 56 Rest of the world Gene Therapy Market 2018 - 2030 (USD Million)